Savara completes enrollment of pivotal phase 3 impala-2 trial of molgramostim nebulizer solution (molgramostim) in autoimmune pulmonary alveolar proteinosis (apap)

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal phase 3 impala-2 trial. a total of 164 patients were randomized. target enrollment for the trial was 160 patients. the company expects to report top line results by the end of 2q 2024. impala-2 is a global, 48-week, placebo-controlled clinical trial evaluating molgramostim, a novel inhaled.
SVRA Ratings Summary
SVRA Quant Ranking